GENOVA Inc. AI Stock Analysis
Want to see JP:9341 full AI Analyst Report?
GENOVA Inc. (9341) AI Stock Analysis
GENOVA Inc.
(TSE/TYO:9341)
GENOVA Inc. achieves a moderate overall score, buoyed primarily by a highly attractive 5.17% dividend yield and a fortress balance sheet with minimal debt. However, these strengths are heavily clouded by severe recent contractions in operating profitability and cash flow generation, which present notable long-term risks. Furthermore, bearish technical momentum indicates current market hesitation, making it a mixed proposition requiring stabilization in profit margins before a higher rating can be justified.
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.61B
- Dividend Yield
- 5.33%
- Average Volume (3M)
- 62.88K
- Price to Earnings (P/E)
- 14.9
- Beta (1Y)
- 0.64
- Revenue Growth
- 46.39%
- EPS Growth
- 12.53%
- Country
- Japan
- Employees
- 529
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Software - Application
GENOVA Inc. Business Overview & Revenue Model
Company Description
Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, s...
GENOVA Inc. Financial Statement Overview
Summary
GENOVA Inc. presents a polarized financial profile. Positives include strong top-line revenue growth and a highly resilient balance sheet with a minimal debt-to-equity ratio of 0.11. However, this is heavily offset by a severe deterioration in operating margins (dropping to 3.5%), an 80% plunge in net income, and a concerning shift toward negative free cash flow.
Income Statement
45NeutralBalance Sheet
85Very PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.77B | 11.57B | 10.01B | 8.68B | 6.51B | 4.80B |
| Gross Profit | 6.76B | 6.47B | 7.38B | 6.55B | 4.79B | 3.50B |
| EBITDA | 513.44M | 543.85M | 2.11B | 2.38B | 1.79B | 1.09B |
| Net Income | 623.48M | 275.40M | 1.41B | 1.73B | 1.26B | 686.27M |
Balance Sheet | ||||||
| Total Assets | 11.31B | 10.26B | 8.53B | 8.20B | 5.41B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 5.08B | 5.32B | 5.87B | 5.97B | 3.86B | 1.65B |
| Total Debt | 1.77B | 735.71M | 20.84M | 377.78M | 28.25M | 163.50M |
| Total Liabilities | 5.16B | 3.36B | 1.53B | 2.16B | 1.37B | 1.33B |
| Stockholders Equity | 6.15B | 6.90B | 7.00B | 6.04B | 4.04B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -46.98M | 1.06B | 1.77B | 1.11B | 513.36M |
| Operating Cash Flow | 0 | 53.85M | 1.19B | 1.82B | 1.20B | 623.77M |
| Investing Cash Flow | 0 | -809.75M | -275.93M | -94.24M | -113.45M | -179.06M |
| Financing Cash Flow | 0 | 199.63M | -1.01B | 376.82M | 1.13B | 59.88M |
GENOVA Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 563.00 is below the 20-day moving average (MA) of 579.25, below the 50-day MA of 598.72, and below the 200-day MA of 588.79, indicating a bearish trend. The MACD of -9.46 indicates Positive momentum. The RSI at 38.63 is Neutral, neither overbought nor oversold. The STOCH value of 34.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.
GENOVA Inc. Peers Comparison
Overall Rating
JP:934159Neutral
JP:448054Neutral
JP:921852Neutral
JP:443846.9Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | JPY 10.04B | 14.89 | ― | 5.33% | 46.39% | 12.53% | |
| 54Neutral | JPY 56.52B | 32.99 | 11.30% | ― | 21.01% | 10.15% | |
| 52Neutral | JPY 7.94B | 29.89 | ― | 1.32% | 34.18% | -32.29% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | JPY 2.16B | -4.71 | ― | ― | 34.13% | 35.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:9341 | GENOVA Inc. | 563.00 | 0.50 | 0.09% | |
| JP:4480 | Medley, Inc. | 1777.00 | -873.00 | -32.94% | |
| JP:4438 | Welby Inc. | 253.00 | -42.00 | -14.24% | |
| JP:9218 | Mental Health Technologies Co. Ltd. | 756.00 | -92.19 | -10.87% | |
| JP:366A | Wellness Communications Corporation | 1062.00 | -168.66 | -13.70% |
GENOVA Inc. Corporate Events
GENOVA Reports Six-Month Results With Sales of ¥7,809 Million
GENOVA Inc. reported consolidated net sales of ¥7,809 million for the six months ended Sept. 30, 2026, up 57.0% year over year. Operating profit was ¥46 million, ordinary profit ¥69 million and profit attributable to owners of the parent ¥358 million...
GENOVA Acquires “Karada ni Iikoto” Healthcare Media Business to Boost Medical Platform
GENOVA Inc. has agreed to acquire the “Karada ni Iikoto” healthcare media business from Central Medience Co., Ltd. for an expected 51 million yen in cash, obtaining contracted editorial services, sponsored content, and PR functions centered on the pl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
